Pasi Janne, MD, PhD
Enriched profileSenior Vice President for Translational Medicine; Director, Lowe Center for Thoracic Oncology; Scientific Director, Belfer Center for Applied Cancer Science; Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Pasi Janne is Senior Vice President for Translational Medicine; Director, Lowe Center for Thoracic Oncology; Scientific Director, Belfer Center for Applied Cancer Science; Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 2,385 publications with 127,638 citations (h-index 163); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Pasi Janne as a Highly Cited Researcher (Clinical Medicine, 2019).
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Pasi A. Jänne, MD PHD, is Senior Vice President for Translational Medicine at Dana-Farber Cancer Institute (academic affiliation: Harvard Medical School). The public record shows 2,385 publications with 127,638 citations (h-index 163), centered on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 30 companies, 10 NIH-funded awards (2008–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 30 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 60 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 583.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Sponsor: Dana-Farber Cancer Institute
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 13 Oct 2026
30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$21,922openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202510 payments$21,614openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20254 payments$12,975openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
10 NIH research awards on record, funded 2008–2026 per NIH RePORTER. The latest:
- Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Dana-Farber Cancer Inst
FY2024$995,148R35CA220497
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.
Clinical cancer research
Article2026 - BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
Molecular cancer therapeutics
Article2026 - The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors.
Clinical cancer research
Article2026 - Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
JCO precision oncology
Article2025
Most-cited works
by citation count (OpenAlex)- 01
- 02Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer4,505 citations2010
- 03
- 04The landscape of somatic copy-number alteration across human cancers4,138 citations2010
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/pasi-janne-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Pasi-A-Jaenne-39074779
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - ResearchGate
researchgate.net/scientific-contributions/Pasi-A-Janne-11783151
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/pasi-j%C3%A4nne-20b5b3260
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_pasi-j%C3%A4nne-md-phd-is-the-first-incumbent-activity-7028433687176171521-53Zr
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
cancerletter.com/podcastc/20250214_5
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - Other
oncodaily.com/dialogues/oncoinfluencers-pasi-a-janne-dialogue
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - X / Twitter
x.com/dfarberthoracic
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - X / Twitter
x.com/DanaFarber/status/1979511734613209471
- X / Twitter
x.com/StephenVLiu/status/1978715278906216935
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn profile listing title as Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute (SERP snippet corroboration; page itself auth-walled)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biocartis.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Internal Medicine, Brigham and Women's Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Fellowship
Hematology & Oncology, Dana-Farber/Partners CancerCare
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Co-Leader
Lung Cancer Program, Dana-Farber/Harvard Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - Editor
Clinical Cancer Research (AACR journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pressroom.cancer.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- Hope Now Award for Lung Cancer Research
Joan's Legacy: The Joan Scarangello Foundation to Conquer Lung Cancer
2007verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tolremo.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →frontiermeds.com ↗
- Director
Chen-Huang Center for EGFR Mutant Lung Cancers, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - David M. Livingston
MD Chair, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Scientific Advisory Board Member
Biocartis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biocartis.com ↗ - Scientific Advisory Board Member
Treadwell Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →treadwelltx.com ↗ - Faculty
CancerGRACE (Global Resource for Advancing Cancer Education)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerstoday.com ↗
- Recurring video/author contributor
OncLive (interviews and expert perspectives on EGFR-mutant NSCLC, FLAURA2 trial, etc.)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - ASCO22 video interview on lung cancer research
Dana-Farber Physician Resources
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicianresources.dana-farber.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Nikhil Munshi, MD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Ignacio Wistuba, MD
Moffitt Cancer Center